University of Manchester spin-out secures £1.75 million investment
Ai2, a spin-out of the University of Manchester, has secured £950,000 from MTI and £800,000 from the North West Fund for Biomedical, managed by Spark Impact. The company has developed proprietary human protein-like substances that safely and cost-effectively inhibit bacteria, fungi and viruses. The products have the potential to be used to prevent infection on a wide range of commonly used medical devices including urinary catheters, stents, orthopaedic implants and wound dressings. Ai2ís humanised cationic peptides are available for exclusive license.
www.a-i-2.com, source: www.bionow.co.uk